Peripheral nerve regeneration through hydrogel enriched chitosan conduits containing engineered Schwann cells for drug delivery by Meyer, Cora et al.
159
Cell Transplantation, Vol. 25, pp. 159–182, 2016 0963-6897/16 $90.00 + .00
Printed in the USA. All rights reserved. DOI: http://dx.doi.org/10.3727/096368915X688010
Copyright Ó 2016 Cognizant, LLC. E-ISSN 1555-3892
 www.cognizantcommunication.com
Received July 29, 2014; final acceptance April 8, 2015. Online prepub date: April 14, 2015.
1These authors provided equal contribution to this work.
Address correspondence to Kirsten Haastert-Talini, Hannover Medical School, Institute of Neuroanatomy, OE 4140, Carl-Neuberg-Str.1, D-30625 
Hannover, Germany. Tel: +49-511-532-2891; Fax: +49-511-532-2880; E-mail: Haastert-talini.kirsten@mh-hannover.de
Peripheral Nerve Regeneration Through Hydrogel-Enriched Chitosan 
Conduits Containing Engineered Schwann Cells for Drug Delivery
Cora Meyer,*†1 Sandra Wrobel,*†1 Stefania Raimondo,‡ Shimon Rochkind,§ Claudia Heimann,¶ 
Abraham Shahar,# Ofra Ziv-Polat,# Stefano Geuna,‡ Claudia Grothe,*† and Kirsten Haastert-Talini*† 
*Institute of Neuroanatomy, Hannover Medical School, Hannover, Lower-Saxony, Germany
†Center for Systems Neuroscience (ZSN) Hannover, Lower-Saxony, Germany 
‡Department of Clinical and Biological Sciences, Università degli studi di Torino, Orbassano, Piemonte, Italy
§Division of Peripheral Nerve Reconstruction, Department of Neurosurgery, Tel Aviv Sourasky Medical Center, 
Tel Aviv University, Tel Aviv, Israel
¶Medovent GmbH, Mainz, Rhineland-Palatinate, Germany
#N.V.R Research Ltd., Ness-Ziona, Israel
Critical length nerve defects in the rat sciatic nerve model were reconstructed with chitosan nerve guides filled 
with Schwann cells (SCs) containing hydrogel. The transplanted SCs were naive or had been genetically modi-
fied to overexpress neurotrophic factors, thus providing a cellular neurotrophic factor delivery system. Prior 
to the assessment in vivo, in vitro studies evaluating the properties of engineered SCs overexpressing glial cell 
line-derived neurotrophic factor (GDNF) or fibroblast growth factor 2 (FGF-218kDa) demonstrated their neurite 
outgrowth inductive bioactivity for sympathetic PC-12 cells as well as for dissociated dorsal root ganglion cell 
drop cultures. SCs within NVR-hydrogel, which is mainly composed of hyaluronic acid and laminin, were 
delivered into the lumen of chitosan hollow conduits with a 5% degree of acetylation. The viability and neu-
rotrophic factor production by engineered SCs within NVR-Gel inside the chitosan nerve guides was further 
demonstrated in vitro. In vivo we studied the outcome of peripheral nerve regeneration after reconstruction 
of 15-mm nerve gaps with either chitosan/NVR-Gel/SCs composite nerve guides or autologous nerve grafts 
(ANGs). While ANGs did guarantee for functional sensory and motor regeneration in 100% of the animals, 
delivery of NVR-Gel into the chitosan nerve guides obviously impaired sufficient axonal outgrowth. This 
obstacle was overcome to a remarkable extent when the NVR-Gel was enriched with FGF-218kDa overexpress-
ing SCs.
Key words: Cellular drug delivery system; Schwann cells (SCs); Sciatic nerve regeneration; 
Fibroblast growth factor-2; Glial cell line-derived neurotrophic factor (GNDF); Chitosan
INTRODUCTION
Lesions to the peripheral nervous system (PNS) follow-
ing traumatic events like car accidents and sport as well 
as military injuries (16,59) are annually reported from 
more than 1 million people worldwide. The degree of 
regained function is dependent on the severity of the injury. 
Spontaneous recovery is possible if the continuity of the 
nerve trunk is preserved, while cases of complete nerve 
transection require surgical intervention (19). Up until now, 
autologous nerve grafts (ANGs) remain the gold standard 
for peripheral nerve reconstruction. Their usage, however, 
implicates certain disadvantages like donor site morbidity, 
limited supply of suitable tissue in case of extended plexus 
injuries, and mismatch issues regarding among others 
axonal size, distribution, and alignment (16). Despite mod-
ern microsurgery techniques, incomplete or incorrect target 
reinnervation is still unavoidable (14,16,29). In conse-
quence, patients experience deficits in sensory and motor 
function and neuropathic pain (8,20,21).
Artificial nerve guides of various biodegradable mate-
rials have been tested as alternatives to ANGs and are 
known to provide a regeneration-promoting environment 
for regrowing axons (38). Nevertheless, clinical usage of 
FDA- or CE-approved hollow nerve guides is so far lim-
ited to bridge nerve defects of up to a maximum length 
of 3 cm. Furthermore, results after artificial nerve graft-
ing are also variable and often insufficient with regard to 
functional recovery (9,16,43).
160 MEYER ET AL.
In order to enhance the rate of successful regenera-
tion across long gaps reconstructed with artificial nerve 
guides, luminal enrichment with filaments, sponges, or 
hydrogels containing collagen or laminin has been con-
sidered (13,16,17,19). Three-dimensional guidance struc-
tures within the conduit may be advantageous to support 
Schwann cell (SC) migration and axonal outgrowth (13). 
To further enhance the chance of successful regenera-
tion across long defects, the addition of regeneration-
supporting cells, such as SCs, as well as the exogenous 
administration of neurotrophic factors has been brought 
into research focus (31,51).
In the current study, we enriched hollow conduits made 
of chitosan with a fine-tuned 5% degree of acetylation, with 
NVR-Gel as a luminal filler, and added genetically modi-
fied neonatal rat SCs as cellular drug delivery system.
The chitosan conduits used in this study have previ-
ously been evaluated in a rat model of 10-mm gap repair, 
where they demonstrated a support of functional regen-
eration similar to ANGs for the reconstruction of 10-mm 
gaps (34). Furthermore, the performance of the chitosan 
conduits has been investigated in critical gap length repair 
(15-mm rat sciatic nerve gap), and their usage resulted in 
a 57% success rate (functional and axonal regeneration) 
in comparison to complete failure of the classic silicone 
tube approach (23).
To structure the hollow lumen of the chitosan conduits 
in the current study, we utilized NVR-Gel, a hydrogel 
composed mainly of high molecular weight hyaluronic 
acid (3 × 106 Da) and laminin that has been developed as 
a regenerative matrix for nerve repair (65). NVR-Gel has 
already demonstrated valuable properties allowing neu-
rite outgrowth in vitro (53,79).
To additionally deliver regeneration supporting neu-
rotrophic factors with the nerve conduit, we used somatic 
ex vivo gene transfer to transplanted SCs. Nonvirally 
transfected neonatal rat SCs overexpressing isoforms 
of fibroblast growth factor-2 (FGF-2) have already 
demonstrated specific support of axonal regeneration 
across 15-mm sciatic nerve gaps, when delivered within 
Matrigel-filled silicone conduits (32,68). The FGF-2 sys-
tem is specifically regulated after peripheral nerve injury 
as it is described that SCs as well as macrophages at 
the lesion site express FGF-2 isoforms and FGF recep-
tors (26,28). Following nerve transection, the isoforms 
are differently regulated with an overall increase of all 
three isoforms in the proximal nerve stump (more pro-
nounced upregulation of FGF-218kDa and FGF-221kDa than 
of FGF-223kDa) (52). Especially the low molecular weight 
isoform FGF-218kDa is upregulated within hours following 
nerve crush (25) and has been shown to endorse axonal 
outgrowth in the long gap peripheral nerve regeneration 
model, and to improve neurite outgrowth of spinal motor 
neurons (1,2,28).
Another promising candidate for drug delivery of 
regeneration-promoting proteins is glial cell line-derived 
neurotrophic factor (GDNF), which is known to act as 
a survival factor for motor neurons and has a promot-
ing effect on SC proliferation as well as on myelination 
(11,38,48). GDNF has been shown to be upregulated in 
SCs at the sciatic nerve transection site peaking at 7 days 
after lesion (37). Supporting its important role in periph-
eral nerve regeneration, impaired regeneration following 
chronic axotomy has been associated with a decline of 
GDNF expression by chronically denervated SCs (37). 
In the current study, we suspended naive or genetically 
engineered SCs in NVR-Gel and injected the suspension 
as a luminal filler and drug delivery system into hollow 
chitosan tubes. We proved survival of the SCs within 
the composite conduits in vitro over a period of 9 days. 
We further demonstrate that the cells populate the inte-
rior NVR-Gel matrix, while demonstrating their typi-
cal bipolar morphology. We then reconstructed a defect 
of 15-mm critical length in the rat sciatic nerve model. 
Reconstruction conditions and animal groups were set 
as follows: ANGs as positive control, representing the 
clinical gold standard, were compared to chitosan/0.5% 
NVR-Gel conduits containing either naive nontransfected 
neonatal rat SCs (nt-neoSCs), empty vector transfected 
control SCs (tf-neoSCs-EV), GDNF overexpressing SCs 
(tf-neoSCs-GDNF), or FGF-218kDa overexpressing SCs 
(tf-neoSCs-FGF-218kDa). Nerve reconstruction by means 
of cell-free chitosan/0.5% NVR-Gel conduits was per-
formed as an additional control. In order to assess the 
efficiency of peripheral nerve regeneration, functional 
and (histo-) morphometric parameters were evaluated.
Overall, the results obtained indicate a poor recovery 
through NVR-Gel-filled chitosan conduits in general, 
while 100% ANG-grafted animals functionally showed a 
high degree of motor recovery (detected by electrodiag-
nostical techniques) as well as almost complete recovery 
of mechanosensitivity (evaluated with von Frey algesim-
etry). However, delivery of FGF-218kDa-SCs significantly 
helped to overcome impediments for tissue regeneration 
and allowed functional recovery in 57% of the animals, 
emphasizing the role of this factor regarding promotion 
of peripheral nerve regeneration.
MATERIALS AND METHODS
Cell Culture
Neonatal Rat Schwann Cells. Primary culture of 
neonatal rat SCs (neoSCs) was performed as described 
previously (30). Briefly, sciatic nerves were harvested 
from Hannover Wistar rat pups (P1-3, in-house breed-
ing) and enzymatically digested for 50 min. Cells were 
cultured for 24 h in DMEM, 1% P/S, 2 mM L-glutamine, 
1 mM sodium pyruvate, and 10% fetal calf serum (FCS; 
CELLULAR DRUG DELIVERY IN COMPOSITE NERVE GUIDES 161
all PAA Laboratories, Coelbe, Germany) on poly-L-
lysine (PLL)-coated culture flask (PLL; Sigma-Aldrich, 
Munich, Germany). After a 2-day period of incubation 
with 1 mM of arabinoside-c (Sigma-Aldrich) neoSC purity 
was increased by removing contaminating fibroblasts via 
immunopanning with magnetic Dynabeads® (Dynal Biotec 
ASA, Oslo, Norway) coupled to anti-Thy-1 antibodies 
(own production from hybridoma cell line); neoSCs were 
then seeded into a new PLL-coated culture flask. The 
purification procedure was repeated once or twice until 
>90% purity of neoSC cultures was reached; subsequently 
medium 2 mM Forskolin (PAA) was added to the medium 
for culture expansion.
NVR-Gel (NVR Labs Ltd., Ness-Ziona, Israel pro-
prietary) was used as a layer for seeding of neoSCs in 
coculture with PC-12 cells (see below) or dissociated 
DRG cells (see below). Therefore, the NVR-Gel of 1% 
was mixed 1:1 with PC-12 differentiation medium (see 
below) or N2 medium (see below), respectively, to a final 
concentration of 0.5%.
Rat Pheochromocytoma Cell Line (PC-12 Cells). PC-12 
cells [kindly provided by Dr. R. Westermann, Marburg, 
Germany, as described previously (27)] were expanded 
in proliferation medium (DMEM high glucose + 10% 
horse serum + 5% FCS + 4 mM L-glutamine + 1 mm sodium 
pyruvate + 100 U/ml penicillin/streptomycin (Pen/Strep; 
all Gibco, Darmstadt, Germany), and for neuronal dif-
ferentiation experiments, the medium was changed to 
differentiation medium (DMEM + 1% horse serum + 1% 
FCS + 4 mM L-glutamine + 1 mm sodium pyruvate + 100 U/ 
ml Pen/Strep).
Primary Dissociated Dorsal Root Ganglion (DRG) 
Cells. As described previously (76), DRGs were dissected 
from neonatal Hannover Wistar rat pups (P1-P3, in-house 
breeding) and collected in HBSS medium (PAA) and 
incubated in HBSS, 0.125% trypsin, 0.1% DNase (Roche 
GmbH, Mannheim, Germany) for enzymatic digestion over 
20 min at 37°C. A following 25-min period of digestion 
with 0.0075% collagenase IV (0.1% stock; Worthington 
Biochemical Cooperation, CellSystems GmbH, Troisdorf 
Germany) was stopped by adding N2 medium [DMEM/
F-12, 1 × N2 supplement + 1% Pen/Strep + 2 mM L-glu-
tamine, 1 mM sodium pyruvate + 0.25% bovine serum 
albumin (BSA; PAA) with 3% FCS (PAA)]. Finally, DRG 
cells were mechanically dissociated to a homogenous 
suspension using a fire-polished glass Pasteur pipette.
Nonviral Genetic Engineering of Cells
Both SCs and PC-12 cells were genetically modified 
using the AMAXA nucleofection technique (Amaxa device 
II; Lonza, Cologne, Germany). Nonviral plasmids were 
derived from the pCAGGS-empty vector as described previ-
ously (57) and as follows: plasmids encoding for enhanced 
green fluorescent protein (EGFP; pCAGGS-EGFP-Flag) 
and low molecular weight FGF-2 (pCAGGS-FGF-2-18kDa-
Flag; NCBI GenBank accession NM_019305.2, 533–994 
bp) as described in Ratzka et al. (61), and the plasmid encod-
ing for GDNF (pCAGGS-GDNF-Flag) was constructed 
by PCR-based cloning of the rat GDNF coding sequence 
(NCBI GenBank accession NM_019139.1, 50-682 bp) by 
Dr. Andreas Ratzka as described elsewhere (53). The in-
frame cloned c-terminal 3× Flag tag of the pCAGGS-Flag 
vector backbone enabled convenient detection of all three 
proteins (EGFP-Flag, FGF-2-18kDa-Flag, and GDNF-Flag) 
with the same antibody.
After transfection, cell survival was determined for a 
cell aliquot by trypan blue (Sigma-Aldrich) staining in 
the Neubauer chamber system (Carl Roth & Co GmbH, 
Karlsruhe, Germany). For transfection, 2.5 × 106 cells 
were suspended in 90 ml basic transfection solution (basic 
glial cell nucleofection kit for SCs or cell line nucleofec-
tion kit for PC-12 cells; both Lonza) and mixed with 5 mg 
of the respective plasmid DNA. Nucleofection occurred 
in AMAXA-specific cuvettes using the program T20 
(SCs) or U29 (PC-12 cells). The reaction was stopped by 
adding 900 ml RPMI medium (Gibco) supplemented with 
10% FCS, after which the cells were processed into the in 
vitro or in vivo experiments described below.
In the current study, we used for in vitro and in vivo 
studies 1) nontransfected neoSCs (nt-neoSCs), and the 
following genetically engineered SC types: 2) empty vec-
tor transfected SCs (tf-neoSCs-EV), 3) EGFP-expressing 
neoSCs (EGFP-neoSCs), 4) GDNF overexpressing 
neoSCs (tf-neoSCs-GDNF), and 5) FGF-218kDa overex- 
pressing neoSCs (tf-neoSCs-FGF218kDa). For in vitro stud-
ies, we further used (B) EGFP-expressing PC-12 cells 
(EGFP-PC-12).
Protein Detection by SDS Gel Electrophoresis 
and Western Blot Analyses
Overexpression of FGF-218kDa and GDNF by tf-neoSCs 
(passages 5–9) was confirmed in Western blot analyses. 
Therefore, cell culture supernatants were collected and 
cell lysates prepared in 1% sodium dodecyl sulfate buf-
fer (SDS; Roth GmbH) prior to denaturation at 95°C and 
sonification for 15 min. For each sample, a calculated pro-
tein concentration of 50 mg was prepared in 2× Laemmli 
buffer 1970 (5×, 0.25 M Tris HCl pH 8.0, 25% glycerol, 
7.5% SDS, 0.25 mg/ml bromphenol blue, 12.5% v/v mer-
captoethanol; all Sigma-Aldrich). Following SDS poly-
acrylamide gel electrophoresis (15% gels), the separated 
proteins were transferred to a nitrocellulose membrane 
(RPN68D; Amersham Bioscience, Freiburg, Germany) 
by electrophoresis (62). Following immune detection of 
FGF-218kDa, GDNF, or Flag-Taq in the ECL system (Intas 
Science Imaging, Göttingen, Germany) using monoclo-
nal anti-FGF-2 (1:1,000, 05-118; Merck Millipore, Merck 
162 MEYER ET AL.
KGaA, Darmstadt, Germany) antibody, polyclonal anti-
GDNF (1:200, sc328; Santa Cruz Biotechnology Inc., 
Heidelberg, Germany) antibody or anti-Flag (1:3,000, 
F18-04; Sigma-Aldrich) antibodies, incubation with the 
secondary horseradish peroxidase (HRP)-coupled anti-
bodies (1:4,000, NA931V or NA934V; Amersham Bio-
science Europe, Freiburg, Germany) was performed. 
Protein signals were visualized with a substrate solution 
(WBKLS0500, Immobilon; Merck Millipore).
Neuronal Differentiation of PC-12 Cells Induced by 
Genetically Different NeoSCs
Induction of neurite formation by EGFP-PC-12 cells 
in coculture with nt-neoSCs or tf-neoSCs-FGF-218kDa was 
compared to that induced by recombinant human FGF-2 
(17.2 kDa) (100-18B; PeproTech GmbH, Hamburg, 
Germany). Therefore, 30 × 104 EGFP-PC-12 cells were 
mixed with 40 × 104 neoSCs prepared in their cell-specific 
culture medium and transferred in a volume of 1 ml in 
0.5% NVR-Gel (1:1 in PC-12 differentiation medium) 
for seeding into a 24-well plate (Nunc; Thermo Fisher 
Scientific, Schwerte, Germany). For control conditions, 
50 ng/ml FGF-218kDa was added to PC-12 differentia-
tion medium, which was mixed with NVR-Gel to a final 
concentration of 0.5% before EGFP-PC-12 cells were 
added. After 5 days in vitro (DIV 5), cells were fixed 
with 6% paraformaldehyde (PFA; Sigma-Aldrich) and 
microscopically analyzed using Cell P (Olympus IX70, 
Hamburg, Germany). The analysis was performed in 
three independent biological replicates.
Neurite Outgrowth From Dissociated DRG Cells 
Induced by Genetically Different NeoSCs
A number of 40 × 104 nt-neoSCs, tf-neoSCs-GDNF, 
or tf-neoSCs-FGF-218kDa were suspended in 1 ml 0.5% 
NVR-Gel (1:1 with N2 medium) and plated into a 24-well 
plate. After 24 h, 2.5 × 103 freshly dissociated DRG cells 
were placed as a drop in the middle of the neoSC-containing 
NVR-Gel layer. After an additional 24 h, the cultures 
were fixed with 6% PFA and processed for immuno-
cytochemistry. Unspecific antibody binding sites were 
blocked with phosphate-buffered salt solution (PBS; 
Biochrom, Berlin, Germany)/0.3 Triton X-100 (Roche 
GmbH)/3% normal goat serum (NGS; Gibco)/2% bovine 
serum albumin (BSA; PAA) solution for 1 h at room tem-
perature (RT). This was followed by overnight incubation 
with neuron-specific anti-b-III-tubulin antibody (1:400, 
ab78078; Abcam, Cambridge, UK) and SC-specific 
anti-S100 antibody (1:1,000, Z0311; Dako, Glostrup, 
Denmark) in PBS/0.3%Triton X-100/1% NGS/1%BSA 
at 4°C. The staining was finalized by an incubation with 
Alexa-555-labeled goat anti-mouse IgG secondary anti-
body and Alexa 488-labeled goat anti-rabbit secondary 
(both 1:500; Invitrogen, Darmstadt, Germany) for ~1.5 h 
at RT. All cell nuclei were counterstained with the nuclear 
dye 4¢,6¢-diamino-2-phenylindole (DAPI, 1:1,000 in 
PBS; Sigma-Aldrich). Neurite morphology was analyzed 
in fluorescence microscopy (Olympus IX70), and for 
every experimental setting, eight single photomicro-
graphs were digitalized in 4× magnification and ana-
lyzed in a merged picture using ImageJ software (NIH, 
Bethesda, MD, USA). For each sample, the perimeter of 
the DRG drop was manually drawn (Polygon selection 
tool) and automatically enlarged (Edit-Selection-Enlarge 
tool) to create concentric curves at a fixed distance 
(from 500 to 1,100 mm) between each other. The number 
of intersections of neuritic processes with the different 
curves was then counted and represented as mean values. 
Additionally, the maximum neurite lengths originating 
from the DRG drop cultures were analyzed for the 10 long-
est neurites. The analysis was performed in three inde-
pendent biological replicates.
Manufacturing of Chitosan Conduits
Extraction of medical-grade chitosan from Pandalus 
borealis shrimp shells was performed by Altakitin S.A. 
(Lisbon, Portugal). Chitosan conduits with a degree of 
acetylation of 5% were produced by Medovent GmbH 
(Mainz, Germany) following a protocol of repeated wash-
ing and hydrolysis steps as described previously (34). All 
manufacturing processes were in accordance with ISO 
13485 requirements and specifications.
Preparation of Genetically Engineered NeoSCs 
for Transplantation Within Composite Chitosan 
Nerve Conduits
To analyze the metabolic viability, the protein expres-
sion levels, and the cellular distribution within composite 
nerve conduits, immediately after eventual transfection, 
1 × 106 genetically different neoSCs (nt-neoSCs, tf-neoSCs- 
FGF-218kDa, tf-neoSCs-GDNF) were suspended in 0.5% 
NVR-Gel prepared with serum-free N2 medium. The 
cell-seeded composite conduits were placed into cell cul-
ture plates and additionally covered with 1 ml of 0.5% 
NVR-Gel in order to avoid drying of the conduits and 
incubated until follow-up evaluation in humidified atmo-
sphere with 5% (v/v) CO2.
For transplantation into our animal model, 2.5 × 106 
neoSCs (passages 8–10) were genetically modified as 
described above 3 days prior to surgery. The cells were 
then cultured for 24 h on PLL-coated six-well plates 
(Nunc; Thermo Fisher Scientific) in SC-specific culture 
medium to recover from transfection. On the same day, 
the medium was changed to serum free-N2 medium. After 
an additional 24 h, a total of 1 × 106 genetically different 
neoSCs (passages 8–9) were mixed with 0.5% NVR-Gel 
(110 ml first set of surgeries and 130 ml second set of sur-
geries) and transferred into chitosan tubes. The conduits 
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were placed into cell culture plates and additionally cov-
ered with 1 ml 0.5% NVR-Gel and incubated overnight 
at 37°C in humidified atmosphere with 5% (v/v) CO2. On 
the following day, conduits containing genetically differ-
ent neoSCs: nt-neoSCs, tf-neoSCs-EV, tf-neoSCs-GDNF, 
tf-neoSCs-FGF-218kDa were transplanted into rat sciatic 
nerve defects as described below.
In order to determine neoSCs purity and transfection 
rates for the transplanted neoSCs, residual cells were 
cultured for immunocytochemical analysis (50 × 104 
cells/24-wells, n = 2 wells/neoSCs type). For monitoring 
SC purity, sample sister cultures were stained for anti-
S100. The transfection rates were determined with anti-
Flag-staining (1:200, F1804; Sigma-Aldrich)/anti-Alexa 
555 (1:500), cell nuclei were counterstained with the 
nuclear dye DAPI (1:1,000 in PBS; Sigma- Aldrich).
For metabolic viability measurements a WST-1 assay 
(Roche GmbH) was performed as previously described 
(76), neoSCs were flushed out of composite chitosan con-
duits (n = 3/condition) after 24 h and seeded into PLL-
coated 24 wells in N2 medium supplemented with 3% 
FCS. Cell adhesion was allowed to take place for 1.5 h 
before the medium was removed and substituted by the 
WST-1 solution mixed 1:10 with N2 medium. A volume 
of 350 ml was added to each well. After 3.5 h of incuba-
tion, the reduced solution was transferred in triplicates 
into a 96-well plate (Nunc; Thermo Fisher Scientific) and 
measured at 450 nm.
To evaluate the protein expression of neoSCs 24 h 
after transferring them into composite chitosan conduits 
(n = 3 conduits/condition), the cells were also flushed out 
with N2 medium and centrifuged, the pellets were washed 
with PBS and centrifuged another time before the pellets 
were stored at −80°C prior to Western blot analysis as 
described above.
To analyze the cellular distribution within the com-
posite chitosan tubes, EGFP-neoSCs suspended in 0.5% 
NVR-Gel were transferred into the conduits and consecu-
tively monitored with fluorescence microscopy (Olympus 
IX70) for up to 9 days (DIV 1, 5, and 9) in vitro.
Animals and Surgical Procedure
All animal experiments followed the German Animal 
Protection Act and were approved by the local animal 
protection committee (Animal care committee of Lower 
Saxony). Adult female Wistar rats (225–250 g) were 
obtained from Janvier [Genest Saint Isle (Le), France] 
and housed in groups of four under standard conditions 
(RT 22.2°C; humidity 55.5%; light–dark cycle 14 h/10 h). 
Food and water were available ad libitum for the com-
plete duration of the experiments.
During surgery and electrodiagnostic recordings, the 
rats were generally anesthetized by an intraperitoneal injec-
tion of chloral hydrate (370 mg/kg; Sigma-Aldrich), and 
sufficient analgesia was ensured by intramuscular injec-
tion of buprenorphine (0.045 mg/kg, Buprenovet®; Bayer 
Pharmaceuticals, Lerverkusen, Germany). On the 2 days 
following the initial surgery, the animals also received butor-
phanol tartrate (0.5 mg/kg, Torbugesic®; Pfizer GmbH, 
Berlin, Germany) via subcutaneous injection as pain 
relief. Additionally, amitriptyline hydrochloride (9 mg/kg/
day, Amitriptylin-neuraxpharm®; Neuraxpharm Arznei-
mittel GmbH, Langenfeld, Germany) was administered 
through the drinking water, starting 2 weeks prior to the 
surgery until the end of the observation period to mini-
mize eventual automutilation events (55).
Animals were prepared for surgery as described previ-
ously (34). In short, the left sciatic nerve was exposed 
under sterile conditions and the wound was kept open 
using small self-made retractors similar to the technique 
described by Bozkurt et al. (12). The gluteus muscle 
served as a landmark to allow transection of the sciatic 
nerve at a constant point. Five millimeters of the distal 
nerve end was removed, and composite chitosan conduits 
(length 19 mm) were implanted to bridge a critical nerve 
defect of 15 mm length. In control animals, a reversed 
ANG was implanted. Therefore, the distal nerve end was 
transected 15 mm distal to the first transection point again, 
and the free nerve segment was then flipped to reverse its 
proximodistal orientation and turned 90° around its longi-
tudinal axis before three sutures (9-0, EH7981G, Ethilon; 
Ethicon, Livingston, Scotland) were located 120° apart 
from each other. Besides the ANG control group, four 
experimental groups were analyzed in which the com-
posite chitosan nerve conduits contained 1) nt-neoSCs, 2) 
tf-neoSCs-EV, 3) tf-neo-SCs-GDNF, and 4) tf-neoSCs-
FGF-218kDa. Surgeries were performed on consecutive 
days in two series (n = 4/condition/series). In a parallel 
experiment (performed by Shimon Rochkind at Tel-Aviv 
Sourasky Medical Center, Israel), one group of additional 
animals (n = 10) received chitosan nerve conduits filled 
with 0.5% pure NVR-Gel. On these nerve samples only 
morphological analysis was performed.
Assessment of Functional Recovery
Progress of functional recovery was monitored by cal-
culation of the Static Sciatic Index [SSI, as described pre-
viously (40)], assessment of the mechanical pain threshold 
via von Frey test, serial noninvasive electrophysiological 
measurements, as well as by calculation of the lower limb 
muscle weight ratio upon sacrifice. The investigators were 
blinded to the nerve reconstruction conditions.
Assessment of the Mechanical Pain Threshold (Von 
Frey Test). Plastic compartments were positioned on a 
metallic mesh stand and animals were placed inside the 
boxes and allowed to acclimate to the surrounding for 15 
min. Following habituation, a blunted needle connected 
to a force sensor in a handheld probe (electronic von Frey 
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algesimeter; IITC Inc. Life Science, Woodland Hills, CA, 
USA) was used to stimulate the medial and lateral side of 
the plantar surface of the intact and injured paw. Pressure 
was increased gradually and slowly until withdrawal of 
the examined paw. The applied force needed to induce a 
paw-lifting reaction was displayed as the weight force (g). 
A cutoff value was set to 40 g. This value was also noted 
when no active withdrawal reaction was detectable. The 
paw withdrawal pressure was recorded five times for each 
side, with an interval between the stimuli of at least 3 min, 
and the three steadiest values were used for calculation of 
a mean that was then used for statistical analysis. The test 
was performed three times before surgery for habituation 
and repeated at 1, 4, 9, 12, and 16 weeks after it.
Serial Noninvasive Electrodiagnostic Recordings. 
Muscle reinnervation was analyzed through noninva-
sive electrodiagnostic measurements 9, 13, and 17 weeks 
after nerve reconstruction as described previously (34). 
In short, a portable electrodiagnostic device (Key-
point Portable; Medtronic Functional Diagnostics A7S, 
Skovlunde, Denmark) was used to stimulate the sciatic 
nerve with single electrical pulses (100 ms duration and 
supramaximal intensity) by transcutaneous placement 
of monopolar needles (30 G, diameter 0.3 mm, length 
10 mm; Natus Europe GmbH, Planegg, Germany). For 
the recordings, the animals were placed and fixed in a 
standardized prone position with the hindlimbs extended. 
Stimulation electrodes were always put at the same land-
marks: proximal electrodes at the sciatic notch and distal 
electrodes into the popliteal fossa. The distance between 
the proximal and distal stimulation points was used to cal-
culate the nerve conduction velocity (NCV). Recording 
electrodes were inserted into the tibialis anterior (TA) or 
plantar (PL) muscles to detect evoked compound muscle 
action potentials (CMAPs). The data gained from suc-
cessful recordings were used to calculate the NCV ratio, 
area under the curve, and amplitude ratio, with the latter 
two providing information with regard to functional axon 
loss or recruited axons, respectively. NCV and amplitude 
ratios were calculated by using values obtained from the 
healthy side as reference (ipsilateral lesioned side/con-
tralateral healthy side).
Muscle Weight Ratio. The TA muscles as well as gas-
trocnemius muscles of all animals were harvested after 
finalizing the functional tests and their fresh (wet) weight 
was noted to calculate the muscle weight ratio (ipsilateral 
lesioned side/contralateral healthy side).
Histological Evaluation
The animals were sacrificed (in deep anesthesia in a 
CO2 atmosphere with final cervical dislocation), and con-
nective tissue or peripheral nerve tissue was subjected to 
fixation by immersion in specific solutions as described 
in the following, since transcardial perfusion was not 
found obligatory for the chosen evaluations.
Analysis of Connective Tissue Surrounding the Nerve 
Conduits. Connective tissue that had developed around 
the different composite nerve conduits was explanted 
(n = 4–6 each group) and prepared for histological analy-
sis as described previously (34). Seven-micrometer-thick 
sections were cut from the distal end of the samples, 
and four sections within a distance of 300 mm were sub-
jected to hematoxylin and eosin (H&E) staining (Roth 
GmbH) and analyzed with regard to number of multi-
nucleated giant cells (MGCs), tissue thickness, and area. 
Additional two sections obtained from the distal end, 
covering a distance of approximately 300 mm, were 
stained for activated macrophages. Therefore, paraffin 
cross sections were incubated in PBS with 3% milk pow-
der (Heirler Cenovis GmbH, Karlsruhe, Germany) and 
0.5% Triton X-100 for blocking before incubation with 
primary mouse anti-ED1 antibody (1:1,000 in blocking 
solution, MCA341R; AbD Serotec, Puchheim, Germany) 
at 4°C overnight. After washing in PBS and incubation 
with Alexa 555-conjugated secondary goat-anti-mouse 
antibody (1:1,000; Invitrogen) for 1 h at RT, counter-
staining with DAPI (1:2,000) was performed for 2 min 
at RT. Finally, the stained samples were mounted with 
Mowiol (475904; Calbiochem, San Diego, CA, USA). 
Four photomicrographs per section were acquired (IX70 
microscope; Olympus), and cell counting was performed 
as described previously using ImageJ software (NIH, 
Bethesda, MD, USA) (34).
Assessment of the Regenerated Nerve Tissue. Regen-
erated nerve tissue was carefully removed from the sur-
rounding chitosan and fixed in 4% PFA (overnight at 
4°C) for subsequent paraffin embedding and (immuno-) 
histological analysis. Chitosan conduits only containing 
thin regenerated tissue were left intact, eventually with 
connective tissue around and entirely processed for par-
affin embedding. Furthermore, in cases of failed regen-
eration, single proximal nerve stumps were processed for 
histological analysis.
Seven-micrometer cross sections obtained from sam-
ples showing clear tissue regeneration as well as repre-
sentative proximal nerve stumps gained from cases of 
failed regeneration were cut starting from the distal end, 
covering a distance of approximately 600 mm. After dis-
carding a 1.5-mm piece of the sample, a second series 
of 600 mm was cut and gathered for histological analy-
sis. Exemplary samples of thin as well as failed tissue 
regeneration were additionally cut in the middle of the 
tube, and sections were gathered covering a distance of 
about 300 mm.
Two sections of each series were H&E stained and 
evaluated with regard to the number of MGCs, while 
CELLULAR DRUG DELIVERY IN COMPOSITE NERVE GUIDES 165
adjacent sections were subjected to ED1 and NF200 
staining to enable counting of activated macrophages 
and visualizing of regenerated axons. For the latter, sec-
tions were subjected to ED1 staining as described above 
followed by a second blocking step and subsequent 
overnight incubation with primary rabbit anti-NF200 
antibody (1:500; N4142; Sigma-Aldrich). After washing, 
incubation with Alexa 488-conjugated secondary goat-
anti rabbit antibody (1:1,000; Invitrogen) for 1 h at RT 
and counterstaining with DAPI (1:2,000) was performed 
Figure 1. Results of Western blot analysis of cell lysates from naive or genetically engineered Schwann cells. Detection of FGF-218kDa and 
pro-GDNF overexpression by Western blot analyzes of cell lysates from nt-neoSCs, tf-neoSCs-EV, tf-neoSCs-FGF-218kDa, or tf-neoSCs-
GDNF (A) cultured for 24 h in regular culture conditions or (B) flushed out of composite chitosan tubes 24 h after seeding and 48 h after 
transfection. (C) Mature GDNF was detected in cell culture supernatants from genetically modified neoSC after 72 h and 120 h. Each n = 3.
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prior to section mounting. Up to five images (magnifica-
tion: 20×) were acquired per section (depending on the 
sample diameter), and counting of activated macrophages 
was performed with the help of ImageJ software.
Nerve Morphometry. Segments of 5-mm lengths 
were cut off the distal nerve segment at 2 mm distal to 
the distal suture site and processed for myelin staining 
and araldite resin embedding and stereological analy-
sis as described previously (22,34). Therefore, the har-
vested tissue was subjected to a fixation according to 
Karnovsky (2% PFA and 2.5% glutaraldehyde in 0.2 M 
sodium cacodylate buffer) prior to postfixation in 1% 
OsO4. Following dehydration in an ethyl alcohol row, 
the samples were delivered to the partner laboratory 
at the University in Turin for embedding in a mixture 
of Araldite resin. Semithin cross sections of samples 
of the functionally recovered nerves were subjected to 
morphometric analysis in order to determine the mean 
total number of regenerated myelinated axons in the 
nerve segment distal to the reconstructed nerve gap as 
well as the mean nerve fiber density, the mean axonal 
diameter, fiber diameter, myelin thickness, and g-ratio. 
Additionally, the same analysis was performed on 10 
distal nerve segments from healthy contralateral nerves 
of the animals included in this study.
Statistical Analysis
The data obtained were subjected to Kruskal–Wallis test 
or two-way ANOVA (analysis of variance) followed by 
Dunn’s or Tukey’s multiple comparisons test (GraphPad 
Prism 6) as indicated in the Results section. Results are 
presented as median ± range or mean ± standard error of the 
mean (SEM) and p values were set at p < 0.05, p < 0.01, and 
p < 0.001 as level of significance.
RESULTS
Prior to modifying hollow chitosan conduits with the 
luminal filler, 0.5% NVR-Gel containing neoSCs as a 
drug delivery system, we evaluated the expression levels 
of the proteins of neoSCs 24 h after transfection and regu-
lar culture as well as 24 h after seeding them into compos-
ite chitosan conduits (48 h after transfection) in Western 
blot analysis. Successful overexpression of FGF-218kDa 
and GDNF was revealed by strong bands in Western blots 
from cell lysates of both regular cell cultures (Fig. 1A) 
and composite chitosan conduits (Fig. 1B), while endog-
enous FGF-218kDa expression was only detected at very 
low levels in cell lysates from cultured nt-neoSCs and 
tf-neoSCs-EV. Regarding the overexpression of GDNF, 
an additional analysis was performed because cell lysate 
analysis 24 h and 48 h after transfection revealed strong 
bands mainly for pro-GDNF. To demonstrate that also the 
expression of mature GDNF is increased, we cultured tf-
neoSCs-GDNF for up to 120 h and detected GDNF levels 
within the cell culture supernatant (Fig. 1C). Five days 
after transfection, not only pro-GDNF but also mature 
GDNF have been released into the cell culture superna-
tant in detectable amounts. The secretion of pro-GDNF 
earlier to the fully processed protein is very likely depen-
dent on the plasmid transfection performed. In contrast 
to previous descriptions about GDNF synthesis as a pre-
cursor and secretion as a mature protein, recent studies 
documented its secretion also as unprocessed pro-GDNF 
in cell culture due to plasmid transfection (47,60,67).
Figure 2. Results of the PC-12 cell neurite outgrowth assay. (A) Bar graph presenting lengths of induced neurite formation by EGFP-
PC-12 cells in NVR-Gel supplemented with 50 ng/ml of free recombinant FGF-2 or cocultured with nt-neoSCs or tf-neoSCs-FGF-218kDa. 
Mean ± SEM, n = 3, **p < 0.01, ***,### p < 0.001, one-way ANOVA with Tukey’s multiple comparison test; ** and ***differences to free 
recombinant FGF-2; ###differences between nt-neoSCs and tf-neoSCs-FGF-218kDa. (B) Sample photomicrograph demonstrating long 
neurite formation of an EGFP-PC-12 cell in the presence of tf-neoSCs-FGF-218kDa.
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Genetically Engineered tf-neoSCs Demonstrate 
Neurite Inductive Bioactivity in 3D-NVR-Gel-Based 
Culture Systems
Two cell culture models were used to evaluate the bio-
activity of genetically engineered neoSCs embedded in 
0.5% NVR-Gel. In the PC12-cell neuronal differentiation 
model, we assessed a traditional sympathetic neuronal 
cell line in a classic neurite outgrowth assay (73), while 
we evaluated sensory neuron outgrowth with our dissoci-
ated DRG cell drop cultures.
In the PC-12-neurite outgrowth assay, we exclusively 
evaluated the bioactivity of nt-neoSCs and tf-neoSCs-
FGF-218kDa and compared it to the bioactivity of free 
recombinant FGF-2 because PC-12 cells are not sensitive 
to GDNF. As demonstrated in Figure 2A, free recombinant 
FGF-2 induced significantly increased neurite outgrowth by 
PC-12 cells when compared to nt-SCs. The neuronal differ-
entiation was further significantly increased when PC-12 
cells were cultured together with tf-neoSCs-FGF-218kDa 
(Fig. 2A, B).
In the DRG drop culture model, however, no signifi-
cant difference in the neurite inductive effects between 
nt-neoSCs or tf-neoSCs were detectable, irrespective of 
if DRG drops were cultured in the presence of tf-neoSCs-
GDNF or tf-neoSCs-FGF-218kDa. Both the numeric neurite 
outgrowth at certain distances from the dissociated DRG 
cell drop cultures (Fig. 3A) and the maximum neurite 
length extending from them (Fig. 3B) were comparable 
in all culture conditions. A sample culture in the presence 
of tf-neoSCs-FGF-218kDa is shown in Figure 3C.
Figure 3. Results of the neonatal dorsal root ganglion neurite outgrowth assay. (A) Neurite outgrowth of dissociated sensory DRG 
cell drop cultures was evaluated according to the number of intersections (y-axis) and the distance of the neurites grown from the drop 
perimeter (x-axis). (B) Mean length (±SEM, n = 3) of the 10 longest neurites extending from the DRG drop cultures. (C) Sample pho-
tomicrograph of a fluorescence-labeled DRG drop (stained for b-III tubulin, red) cocultured with tf-neoSCs-FGF-218kDa (S-100, green); 
all cell nuclei were counterstained with DAPI (blue).
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Genetically Engineered tf-neoSCs Demonstrate 
Sufficient Metabolic Viability, Develop Their Typical 
Morphology, and Migrate Within NVR-Gel-Enriched 
Com posite Chitosan Conduits In Vitro
Analysis of the WST-1 assay performed 24 h after 
seeding nt-neoSCs or tf-neoSCs into NVR-Gel-filled 
chitosan conduits revealed overall metabolic active 
and viable neoSCs (Fig. 4A). The metabolic activity 
of tf-neoSCs was slightly increased over that of nt-
neoSCs with the strongest reaction seen for tf-neoSCs-
FGF-218kDa (Fig. 4A). Analysis of the cell morphology 
of EGFP-neoSCs monitored over up to 9 days in vitro 
demonstrated aggregated round-shaped cells 24 h after 
seeding in an overview (DIV 1, Fig. 4B). In Figure 4C, 
Figure 4. Metabolic activity and morphology of naive and genetically engineered Schwann cells in NVR-Gel-filled chitosan nerve guides 
in vitro. (A) Bar graph depicting the metabolic viability of nt-neoSCs, tf-neoSCs-FGF-218kDa, and tf-neoSCs-GDNF, which have been flushed 
out from composite chitosan nerve conduits 24 h after seeding (mean ± SEM, n = 3 conduits per condition). (B–E) Cell morphology and 
distribution of neo-SCs within the composite nerve conduits was monitored after seeding of EGFP-neoSCs for up to 9 days in vitro. Arrows 
point to EGFP-neoSCs migrating out of initially formed cell clusters when they also demonstrate their typical bipolar morphology.
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this is shown in higher magnification as well. At DIV 5 
EGFP-neoSCs had migrated out of the initially formed 
cell clusters to populate the NVR-Gel-filled lumen of 
the chitosan tube showing their typical bipolar morphol-
ogy (Fig. 4D). Upon final examination at DIV 9, even 
increased cell numbers with SC typical morphology 
were seen (Fig. 4E).
After we could demonstrate overexpression of bio-
active target proteins by tf-neoSCs within composite 
chitosan nerve conduits together with sufficient cellular 
viability and equal distribution of the cells within the 
nerve conduits, we initiated the in vivo investigations.
Over a time period of 17 weeks, functional evaluation 
of the regeneration progress was performed. As experi-
enced in other studies (34,46), the evaluation of the SSI 
after long nerve defect repair did not reveal any differ-
ences among the groups.
Early Sensory Reinnervation Events Were Detectable 
After Reconstruction With an Autologous Nerve Graft, 
While This Was Rare After Reconstruction With 
Composite Nerve Conduits.
The first signs of sensory recov ery, indicated by the with-
drawal response upon stimulation of the lateral plantar paw 
side of the lesioned hindlimb were detectable 9 weeks after 
nerve reconstruction in all ANG group animals. As depicted 
in Figure 5, the pressure, however, required to elicit this 
response was significantly decreased (12.64 ± 1.26 g) com-
pared to the values obtained from stimulation of the same 
area at the contralateral healthy paw (20.16 ± 0.30 g), indi-
cating hyperalgesia. At the same time, only single animals 
of the nt-neoSCs (n = 1, 18.93 g), tf-neoSCs-GDNF (n = 1, 
20.93 g), and tf-neoSCs-FGF-218kDa (n = 1, 15.60 g) groups 
demonstrated similar signs of reinnervation. Until the end 
of the observation period, no sensory recovery was seen in 
Figure 5. Results of the functional evaluation of mechanical pain thresholds with von Frey algesimetry testing. Bar graph illustrating the 
development of the mechanical pain threshold at the lateral plantar paw of the lesioned versus the contralateral healthy hindlimb over the 
recovery time within the different treatment groups (mean ± SEM). Stimulation of the lateral territory revealed almost sole reinnervation 
in the ANG group, while only single animals responded in the other groups. For statistical analysis, all animals were included, and in 
case of no signal detection, cutoff force values (40 g) were set. Results were tested for significance (p < 0.05) using two-way ANOVA, 
Tukey’s multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 versus values obtained from the contralateral side; #p < 0.05, ##p < 0.01, 
###p < 0.001 versus fellow experimental groups at the same time point, §p < 0.05 versus tf-neoSCs-EV group at the same time point.
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the tf-neoSCs-EV group, while in the ANG group the pain 
threshold increased with ongoing reinnervation until it no 
longer differed significantly from healthy control values of 
the contralateral side (week 12: 15.15 ± 1.59 g; week 16: 
17.76 ± 1.28 g), representing recovery from initial hyperal-
gesia and reestablishment of normal mechanical sensation. 
Also the single animals of the other groups demonstrated 
an increase of the mechanical pain threshold with time after 
surgery, and exclusively in the tf-neoSCs-FGF-218kDa group, 
a second animal was detected with recovering mechanic 
pain sensation at the lateral plantar side of the paw of the 
lesioned hindlimb.
The pain threshold measured in response to stimulation 
of the medial plantar paw side of the lesioned hindlimb, a 
territory that is partly innervated by the saphenous nerve, 
was significantly decreased in all animals following nerve 
transection and repair compared to values obtained from 
the same area of the contralateral healthy paw. These 
signs of hyperalgesia did not recover during the observa-
tion period of 16 weeks.
Motor Recovery Was Sufficient After Autologous 
Nerve Grafting and Achieved a Notable Value Only 
After Transplantation of tf-neoSC-FGF-218kDa Within 
Composite Nerve Conduits.
Recovery of muscle innervation was evaluated by means 
of noninvasive nerve conduction tests at 9, 13, and 17 weeks 
after sciatic nerve transection and reconstruction. The results 
of these measurements are listed in Table 1 for the tibialis 
anterior (TA) muscles and in Table 2 for the plantar (PL) 
muscles. Nine weeks after surgery, reinnervation of the TA 
muscles as well as the PL muscles was already detectable in 
almost all animals of the ANG group, while it was only spot-
ted in a single animal of the nt-neoSCs and tf-neoSCs-EV 
groups, respectively. Thirteen weeks after surgery, com-
pound muscle action potentials (CMAPs) were evocable 
in all animals of the ANG group both from the TA and PL 
muscles. At the same time, the positive recording from one 
tf-neoSCs-EV animal was not confirmed, but a first animal 
of the tf-neoSCs-FGF-218kDa group showed signs of rein-
nervation. Finally, 17 weeks after surgery, CMAPs were 





Ratio NCV Ratio AxL (%)
9 weeks






nt-neoSCs 1/8 0.02 ± 0.02 0.03 ± 0.03 96.79 ± 3.21
tf-neoSCs-EV 1/8 0.01 ± 0.01 0.06 ± 0.06 97.92 ± 2.08
tf-neoSCs-GDNF 0/8 na na na
tf-neoSCs-FGF-218kDa 0/8 na na na
13 weeks






nt-neoSCs 1/8 0.04 ± 0.04 0.04 ± 0.04 96.07 ± 3.93
tf-neoSCs-EV 0/8 na na na
tf-neoSCs-GDNF 1/7 0.04 ± 0.04 0.04 ± 0.04 92.37 ± 7.63
tf-neoSCs-FGF-218kDa 1/8 0.03 ± 0.03 0.04 ± 0.04 94.96 ± 5.04
17 weeks






nt-neoSCs 1/7 0.06 ± 0.06 0.04 ± 0.04 92.99 ± 7.01
tf-neoSCs-EV 0/6 na na na
tf-neoSCs-GDNF 1/7 0.04 ± 0.04 0.03 ± 0.03 91.36 ± 8.64
tf-neoSCs-FGF-218kDa 4/7 0.15 ± 0.06 0.25 ± 0.05 71.78 ± 10.74
Result from noninvasive electrodiagnostical evaluation at different time points after surgery. Data are given as mean ± SEM. 
For statistical analyses, all animals were included, and in case of no signal detection, null values (amplitude ratio, NCV ratio) 
or 100% (AxL) were set. Noninvasive recordings from the tibialis anterior muscles revealed significant differences between the 
autologous nerve graft (ANG) group and all groups that were treated with either of the composite chitosan conduits. Additionally, 
sole treatment with the gold standard ANG led to a significant improvement of muscle reinnervation over time. Results were 
tested for significance (p < 0.05) using two-way ANOVA, Tukey’s multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 
versus values all fellow groups at the same time point; §§p < 0.01 versus ANG 13 weeks; ###p < 0.001 versus ANG 17 weeks. 
Abbreviations: na, not available; NCV, nerve conduction velocity; AxL, axon loss; ANG, autologous nerve graft; nt-neoSCs, 
nontransfected neonatal Schwann cells; tf-neoSCs, transfected neonatal Schwann cells; EV, empty vector; GDNF, glial cell line-
derived neurotrophic factor; FGF-218kDa, fibroblast growth factor 2 (18 kDa isoform).
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recordable from the TA muscle in four out of seven animals 
of the tf-neoSCs-FGF-218kDa group. One of these animals 
further displayed PL muscle reinnervation.
The data gained from the recordings were used to cal-
culate the nerve conduction velocity (NCV) ratio, area 
under the curve (AUC), and amplitude ratio, with the lat-
ter two providing information with regard to functional 
axon loss (%) and an indication of number of conducting 
axons, respectively. Representatively the amplitude ratio 
results calculated from TA muscle CMAPs are illustrated 
in Figure 6 comparing the ANG and tf-neoSC-FGF-218kDa 
groups with continuous improvement of values. The ANG 
treatment enabled recovery of the amplitude size to almost 
50% of contralateral control values at 17 weeks after sur-
gery, while the tf-neoSCs-FGF-218kDa treatment supported 
recovery to 13% of control values. Regarding PL muscle 
reinnervation ANG treatment was superior to all treat-
ments with composite nerve conduits (Table 2).
Calculations of NCV ratio and AUC, with estima-
tion of the functional axon loss, supported the findings 
of the amplitude analysis. During noninvasive TA muscle 
recordings, animals of the ANG group showed significant 
faster NCVs and significantly lower loss of functional 
axons than animals of the experimental groups (Table 1).
In addition to the electrophysiological examination, 
the lower limb muscle weight ratio was determined 
upon sacrifice of the animals as another indicator for 
muscle reinnervation. As depicted in Figure 7, both the 
TA (Fig. 7A) and gastrocnemius (Fig. 7B) muscle weight 
ratio recovered in the tf-neoSCs-FGF-218kDa group to val-
ues no longer significantly different to the ANG group.
Macroscopic Analysis of the Reconstructed Nerves 17 
Weeks After Surgery Indicated That NVR-Gel Might 
Have Impaired In Vivo Regeneration and That This 
Could Partly be Overcome by Suspension of tf-neoSCs-
FGF-218kDa in It
After sacrifice of the animals (17 weeks after surgery), 
the reconstructed nerves were examined, and the results 
are listed in Table 3, and representative photographs are 





Ratio NCV Ratio AxL (%)
9 weeks






nt-neoSCs 0/8 na na na
tf-neoSCs-EV 0/7 na na na
tf-neoSCs-GDNF 0/5 na na na
tf-neoSCs-FGF-218kDa 0/6 na na na
13 weeks





nt-neoSCs 1/8 0.02 ± 0.02 0.06 ± 0.06 97.37 ± 2.63
tf-neoSCs-EV 0/8 na na na
tf-neoSCs-GDNF 0/4 na na na
tf-neoSCs-FGF-218kDa 0/7 na na na
17 weeks






nt-neoSCs 1/7 0.07 ± 0.07 0.07 ± 0.07 92.83 ± 07.17
tf-neoSCs-EV 0/5 na na na
tf-neoSCs-GDNF 1/4 0.02 ± 0.02 0.07 ± 0.07 94.95 ± 5.05
tf-neoSCs-FGF-218kDa 1/6 0.05 ± 0.05 0.04 ± 0.04 91.67 ± 8.34
Results from noninvasive electrodiagnostical evaluation at different time points after surgery. Data are given as mean ± SEM. 
For statistical analyses, all animals were included, and in case of no signal detection, null values (amplitude ratio, NCV ratio) 
or 100% (AxL) were set. Recordings from the plantar muscles revealed that ANG treatment was superior in supporting motor 
recovery to all other experimental groups at each recording time point. Results were tested for significance (p < 0.05) using 
two-way ANOVA, Tukey’s multiple comparisons. *p < 0.05, **p <0.01, ***p < 0.001 versus values of all fellow groups at the 
same time point; §p < 0.05, versus ANG 13 weeks; ##p < 0.01, ###p < 0.001 versus ANG 17 weeks. Abbreviations: na, not 
available; NCV, nerve conduction velocity; AxL, axon loss; ANG, autologous nerve graft; nt-neoSCs, nontransfected neonatal 
Schwann cells; tf-neoSCs, transfected neonatal Schwann cells; EV, empty vector; GDNF, glial cell line-derived neurotrophic 
factor; FGF-218kDa, fibroblast growth factor 2 (18 kDa isoform).
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shown in Figure 8. While also from the functional test, all 
animals of the ANG group were considered as presenting 
regenerated sciatic nerves (Fig. 8A), exclusively suspen-
sion of tf-neoSCs-FGF-218kDa in the NVR-Gel used for 
composite chitosan nerve conduits resulted in substantial 
nerve tissue regeneration (Fig. 8B) in four out of seven 
animals (Table 3). In the tf-neoSCs-FGF-218kDa group, no 
complete failure of tissue regeneration was seen, but in 
the remaining three out of seven animals, only thin con-
nections between the nerve ends were found. Substantial 
nerve tissue was only seen for single animals of the 
other experimental groups. Most of the composite nerve 
Figure 7. Results of the lower limb muscle weight analysis. Bar graphs illustrating the lower limb muscle weight ratio calculated upon 
sacrifice at 17 weeks after surgery for (A) the tibilalis anterior and (B) the plantar muscles (median ± range). Results were tested for 
significance (p < 0.05) using Kruskal–Wallis test, Dunns multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 versus ANG.
Figure 6. Results of the functional evaluation of motor recovery with electrophysiological assessment. Dot blot depicting the ampli-
tude ratio calculated from noninvasive electrophysiological examination at different time points after surgery (mean ± SEM). Results 
were tested for significance (p < 0.05) using two-way ANOVA, Tukey’s multiple comparisons. **p < 0.01, ***p < 0.001 versus ANG 
group at the same time point; ###p < 0.001 versus ANG 17 weeks, §§§p < 0.001 versus ANG 13 weeks.
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conduits from the NVR-Gel alone group, the nt-neoSCs 
group, the tf-neoSCs-EV group, as well as the tf-neoSCs-
GDNF group did not contain any recognizable nerve tis-
sue but eventually a thin tissue connection between the 
reconstructed sciatic nerve ends (Fig. 8C).
Nerve Regeneration Through Composite Nerve Con duits 
Was Not Impaired by Inflammatory Reactions.
In order to analyze if modifying the hollow chitosan 
conduits into composite nerve conduits had an impact on 
the tissue reaction against the material, we histologically 
analyzed the connective tissue that has formed around 
the implanted nerve conduits as well as the nerve tissue 
within them. As an indicator for graft rejection, we first 
analyzed the number of multinuclear giant cells (MGCs) 
that had formed in it during the 17 weeks postoperative 
period (Fig. 9A, B). Only single MGCs were found in 
one out of four animals of the tf-neoSCs-EV group and 
in two out of six animals of the tf-neoSCs-FGF-218kDa 
group. Furthermore, no significant differences among the 
experimental groups were detectable with regard to the 
thickness (Fig. 9C) of the connective tissue as well as its 
area (Fig. 9D).
Samples of substantial nerve tissue regeneration were 
subjected to ED1 (activated macrophages) staining and 
analyzed, but again no obvious differences among the sam-
ples from different groups were seen (data not shown).
Histological Analysis of Proximal Nerve Ends and 
Composite Nerve Conduits Displaying Failed Nerve 
Regeneration Demonstrated Impaired Axonal Regen-
eration Into Nerve Conduits That 17 Weeks After 
Surgery Still Contained Dense Hydrogel Residues in 
Their Lumen
Paraffin sections were obtained close to the proximal 
suture site connecting the composite nerve guide to the 
proximal nerve end as well as 1.5 mm more proximal 
within the proximal nerve end. Sections were double 
stained to detect activated macrophages (ED1) and axons 
(neurofilament 200 kDa, NF200). Again, no increased 
inflammatory reaction was detectable, but failed axonal 
regeneration was obvious as sections at the suture site 
did not or only contain few NF200 immunopositive 
axons entering the composite nerve conduits (Fig. 10A, 
B), while sections far more proximal contained visible 
amounts of axons (Fig. 10C, D).













ANG 7/7 0/7 0/7
nt-neoSCs 1/7 2/7 4/7
tf-neoSCs-EV 1/6 2/6 3/6
tf-neoSCs-GDNF 1/7 2/7 4/7
tf-neoSCs-FGF-218kDa 4/7 3/7 0/7
Inspection of the reconstructed sciatic nerves upon sacrifice of the animals revealed diverse numbers 
of animals per experimental group with substantial nerve regeneration, only thin connections between 
the nerve ends, or no recognizable tissue regeneration. Abbreviations: ANG, autologous nerve graft; 
nt-neoSCs, nontransfected neonatal Schwann cells; tf-neoSCs, transfected neonatal Schwann cells; 
EV, empty vector; GDNF, glial cell line-derived neurotrophic factor; FGF-218kDa, fibroblast growth 
factor 2 (18 kDa isoform).
Figure 8. Representative photomicrographs of explanted speci-
mens following a 4-month observation period. (A) Sciatic nerve 
regenerated through a 15-mm-reversed ANG. (B) Sciatic nerve 
substantially regenerated through a composite chitosan conduit 
filled with tf-neoSCs-FGF-218kDa suspended in NVR-Gel. (C) 
Sciatic nerve reconstructed with a composite chitosan conduit 
filled with tf-neoSCs-EV displaying only a thin connection 
between the bridged nerve ends. Specimens are placed on scale 
paper with 1-mm intersections.
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Morphometric Analysis of Distal Nerve Segments 
Revealed Differences in the Amount of Regenerated 
Myelinated Axons Between Autologous Nerve Grafting 
and Nerve Reconstruction With tf-neoSCs-FGF-218kDa 
Composite Nerve Conduits but no Differences in Axon 
Maturation and Myelination
The results of the morphometric analysis of all distal 
nerve segments originating from reconstructed nerves 
demonstrating functional recovery are listed in Table 4. As 
depicted in Figure 11, we compared the results obtained 
from the ANG group and the tf-neo-SCs-FGF-218kDa group 
with the data obtained from healthy nerves because only 
from those enough data were available for statistical analy-
sis. Autologous nerve grafting resulted in total axon num-
bers significantly higher than in tf-neoSCs-FGF-218lDa or in 
healthy nerves distally to the injury site (Fig. 11A). Nerve 
fiber densities, however, were only significantly different 
between the regenerated nerves of the examined groups 
(Fig. 11A). In comparison to healthy axons, the mean 
axonal diameter, fiber diameter, and the myelin thickness 
were significantly reduced in the regenerated nerve seg-
ments (Fig. 11B). The g-ratio of axons regenerated in the 
tf-neoSCs-FGF-218kDa group was still significantly lower 
compared to healthy nerves, while that of regenerated 
axons in the ANG group did already recover to almost 
physiological levels (Fig. 11B). The distal nerve segment 
of the NVR-Gel alone group was processed for morpho-
metrical analysis only, but again there were not enough 
samples with regenerating fibers to perform a statistical 
evaluation. Regenerating fibers within the distal nerve seg-
ments were only detectable in 1 out of 10 animals (Table 
4). Furthermore, in three samples from this control group, 
few fibers were detectable in the periphery of the analyzed 
cross sections. Figure 12 shows high-resolution images of 
representative semithin sections, stained with Toluidine 
blue, of nerve samples regenerated through an ANG (A), 
a chitosan/NVR-Gel alone conduit (B), and a chitosan/
NVR-Gel/tf-neoSCs-FGF-218kDa conduit (C). Regenerating 
fibers were detectable in the ANG group sample (A) and 
in the chitosan/NVR-Gel/tf-neoSC-FGF-218kDa sample (F), 
Figure 9. Results of the histological examination of the connective tissue formed around the composite nerve grafts. (A, B) 
Representative photomicrographs of single multinuclear giant cells that formed in the connective tissue that had developed around the 
composite nerve conduits. (C, D) Bar graphs illustrating the lack of significant differences between the experimental groups’ connec-
tive tissue thickness (C) and area (D). Results were tested for significance (p < 0.05) using Kruskal–Wallis test.
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whereas in (B) a nerve sample from the NVR-Gel alone 
group, where fibers are regenerated in the outer periphery 
of the cross section, is presented.
DISCUSSION
Studies that address the treatment of long peripheral nerve 
defects have to take into account numerous variables that 
decide whether or not a conduit will successfully support 
peripheral axon regeneration. The clinical gold standard 
treatment for the reconstruction of long peripheral nerve 
defects is the use of autologous nerve tissue. The autologous 
nerve graft is therefore the proper control for preclinical ani-
mal studies evaluating peripheral nerve tissue engineering 
approaches (6). Because of the proregenerative properties 
provided by autologous nerve grafts also the functional out-
come after nerve reconstruction can be adequately addressed 
Figure 10. Results of the histological examination of nerve samples harvested proximal to the grafts. (A, B) Representative photomi-
crographs acquired from sections of proximal nerve stumps from which no or only few axons grew into the composite nerve conduits 
they have been connected to. (C, D) NF200 immunopositive axons were present only 1.5 mm proximal to the proximal suture sites of 
the same samples.
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in a comprehensive study design (6) as it has been chosen 
for the present investigation. We detected high degrees of 
functional motor recovery and almost complete recovery of 
mechanosensitivity in 100% of ANG group animals. High 
percentages of up to 100% of animals demonstrating func-
tional recovery of the sciatic nerve after autologous nerve 
grafting is regularly reported from analyzing motor parame-
ters like the animals’ walking pattern, kinematic data, electro-
physiological examination of lower limb or plantar muscles 
(5,20,34,35,39,46,56,69,70,77). Recovery of sensory func-
tions, especially mechanosensitivity or nociception, is more 
often addressed in studies related to the development of neu-
ropathic pain but usually also recovers to a great extent after 
autologous nerve grafting (41,46,58). Although the PNS has 
an intrinsic capacity to regenerate, problems like misdirec-
tion of axons, insufficient structural support of axonal out-
growth as well as deprivation from regeneration-promoting 
factors can limit the success rate especially across long gaps 
Figure 11. Results of the histological examination of nerve samples harvested distal to the grafts. Comparison of results obtained 
in morphometric analysis of distal nerve segments from the ANG and tf-neoSCs-FGF-218kDa groups. (A) Bar graphs depicting the 
comparison parameters related to the quantification of regenerated myelinated axons. (B) Bar graphs depicting parameters related to 
axonal maturation. Data are given in median ± range. Results were tested for significance (p < 0.05) using Kruskal–Wallis test, Dunn’s 
multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 versus contralateral, healthy control values; ###p < 0.001 versus ANG.

















10/10 8,796.67 ± 464.06 16,598.61 ± 595.05 4.64 ± 0.15 6.94 ± 0.17 1.15 ± 0.03 0.66 ± 0.01
ANG 7/7 11,294.64 ± 769.39 28,306.61 ± 1,610.38 2.15 ± 0.14 3.25 ± 0.19 0.55 ± 0.03 0.65 ± 0.01
NVR-Gel 1/10 8,844.75 17,660.68 2.39 3.67 0.64 0.62
nt-neoSCs 1/7 14,864 44,586 1.81 2.83 0.51 0.63
tf-neoSCs
-EV 0/6 na na na na na na
-GDNF 1/7 12,022 33,240 1.83 2.77 0.47 0.67
-FGF-218kDa 4/7 6,298.62 ± 1,868,64 20,927.33 ± 2,304.59 1.65 ± 0.03 2.72 ± 0.10 0.54 ± 0.04 0.60 ± 0.02
Data are given in mean ± SEM for ANG, tf-neoSCs-FGF-218kDa, and healthy nerve samples, while for single animals with functional recovery, the single 
values are presented. Abbreviations: na, not available; ANG, autologous nerve graft; NVR-Gel, chitosan conduits with solely NVR-Gel; nt-neoSCs, 
nontransfected neonatal Schwann cells; tf-neoSCs, transfected neonatal Schwann cells; EV, empty vector; GDNF, glial cell line-derived neurotrophic 
factor; FGF-218kDa, fibroblast growth factor 2 (18 kDa isoform).
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(4,18,23,34,44). These impediments are the reason why also 
with autologous nerve grafting functional recovery is never 
complete (remains partial) in comparison to healthy con-
trol nerves. With regard to the structural support of axonal 
outgrowth intraluminal fillers such as different hydrogels 
are thought to be favorable, since they potentially support 
migration of host SCs together with axonal outgrowth (16). 
It has also been reported that neurotrophic factor free matri-
ces filling the lumen of hollow nerve conduits result in poor 
regeneration, while the addition of specific neurotrophic fac-
tors generally mediates better regeneration properties than 
empty tubes (59).
In the current study, we therefore aimed at a com-
bined approach of using composite nerve conduits 
composed of hollow chitosan tubes, which had already 
demonstrated nerve regeneration-supporting properties 
(23,34), filled with NVR-Gel. NVR-Gel as a luminal 
filler was supposed to provide a regenerative matrix 
for peripheral axons (65). For the in vivo application 
into nerve conduits, NVR-Gel was used in a concen-
tration/density of 0.5%. This concentration allowed 
its secure injection into the nerve conduits without the 
risk of immediate efflux. Regeneration-promoting neu-
rotrophic factors have been additionally delivered to 
the composite nerve conduits by genetically engineered 
SCs. Physiologically upon nerve transection, the local 
SCs dedifferentiate, start to proliferate, and to migrate 
to the injury site, where they support and guide regrow-
ing axons to the distal targets (54). Consequently, trans-
plantation of SCs within nerve conduits is thought to be 
advantageous and their genetic modification into neu-
rotrophic factor delivery systems has proven to support 
axonal and functional recovery (32,48,59).
NVR-Gel Demonstrates a Discrepancy Between 
In Vitro and In Vivo Properties
The results seen in the current study clearly dem-
onstrate that the viability of SCs suspended in 0.5% 
NVR-Gel and delivered into chitosan nerve conduits is 
not altered and that they develop their typical morphol-
ogy and are able to migrate and to start alignment during 
their time in culture. Furthermore, in vitro 0.5% NVR-
Gel allows neurite extension from PC-12 cells as well 
as dissociated DRG drop cultures. In previous studies, 
NVR-Gel did also demonstrate its favorable properties 
as a regenerative matrix in vitro (79), and it has been 
successfully used in spinal cord reconstruction in vivo 
(63). The mode of application of a hydrogel for spinal 
cord repair, however, differs from that for peripheral 
nerve reconstruction. Still, it was quite surprising to 
us that NVR-Gel as luminal filler in composite chito-
san nerve conduits did not support axonal regeneration, 
when used for reconstruction of 15-mm rat sciatic nerve 
gaps. While hollow conduits did already result in a suc-
cess rate of 57% motor recovery in the same model (23), 
regenerating fibers within the distal nerve segments were 
only detectable in 1 out of 10 animals when adding pure 
NVR-Gel as a luminal filler. Furthermore, in three sam-
ples from this control group, few fibers were detectable 
in the periphery of the analyzed cross sections. These 
results indicate that the NVR-Gel acted as a physical bar-
rier to the regenerating axons. Since the same concentra-
tion/density of NVR-Gel was used in our in vitro and 
in vivo approaches, this finding suggests that NVR-Gel 
properties changed over time within chitosan composite 
nerve conduits and then impaired axonal outgrowth in 
vivo. Such secondary changes may have led to reduction 
of luminal space and reduced speed of NVR-Gel removal 
from the chitosan tubes. For a laminin-containing hydro-
gel, different from NVR-Gel, it was assumed by others 
that due to secondary swelling in vivo initially enhanced 
axonal regeneration was turned into its inhibition (49). 
We have to conclude that the hydrogel may have ham-
pered nerve regeneration through the composite nerve 
conduits, although potentially supportive SCs have been 
suspended within it.
Figure 12. High-resolution images of representative semithin sections, stained with Toluidine blue, of distal nerve samples. Nerve 
samples were harvested after reconstruction with (A) an autologous nerve graft, (B) a chitosan/NVR-Gel alone conduit, (C) a chito-
san/NVR-Gel/tf-neoSC-FGF-218kDa conduit. Particularly, nerve samples from the NVR-Gel alone group (B) demonstrated growth of 
regenerating fibers in the outer periphery of the cross sections. Scale bar: 20 mm.
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Transplantation of Genetically Modified Schwann Cells 
Is an Interesting Tool for Neurotrophic Factor Delivery
Indeed, we successfully demonstrated the survival of 
genetically modified tf-neoSCs in NVR-Gel-filled chitosan 
conduits, as well as their neurite inductive bioactivity in 
cultures of PC-12 cells and dissociated DRG drops in vitro. 
Therefore, the transplanted tf-neoSCs are not supposed to 
have impaired axonal regeneration through the composite 
nerve conduits. Furthermore, we did already demonstrate 
that SCs suspended in MatrigelTM support regeneration 
across rat sciatic nerve defects through silicone conduits 
(32,36). Also others have previously described that col-
lagen nerve guidance conduits seeded with SCs enhance 
rat peripheral nerve regeneration (3,7,59). We additionally 
found no signs of composite nerve guide rejection such as 
massive formation of MGCs or increased tissue infiltra-
tion with activated macrophages. These results are in line 
with data previously obtained with hollow chitosan con-
duits and indicate that our composite nerve conduits have 
been biologically inert (23,34). Again we have to conclude 
that neither the chitosan nerve conduit itself nor the trans-
planted SCs have been an obstacle for regeneration. This 
conclusion is fostered by another study describing that also 
a chitosan/glycerol-b-phosphate disodium salt hydrogel-
containing SCs injected into nerve conduits led to com-
plete failure of regeneration (10-mm gap rat sciatic nerve 
gap), while SCs in suspension or culture medium alone 
allowed regeneration (78).
tf-neoSCs-FGF-218kDa Support Partial Functional 
Recovery Through Composite Nerve Conduits
In addition to the formation of regenerative tissue 
and axonal regeneration, peripheral nerve reconstruction 
should result in functional recovery. With regard to the time 
course and the extent of functional recovery, all composite 
nerve conduits have to compete with the gold standard of 
autologous nerve grafting, which was in the current study 
represented by the ANG group. We mainly evaluated the 
mechanical pain threshold as indicator for sensory recov-
ery, and electrophysiological parameters were assessed as 
a measure for motor recovery. Owing to the fact that only 
in the tf-neoSCs-FGF-218kDa group functional nerve regen-
eration occurred in animal numbers high enough for statisti-
cal comparison to the ANG group, the differences between 
these two groups will be discussed in the following.
Altogether, the obtained results demonstrate the initial 
full sensory denervation of the lateral plantar paw for up 
to a minimum of 4 weeks after nerve injury. Under healthy 
conditions, tibial and sural branches of the sciatic nerve 
as well as the saphenous nerve provide sensory innerva-
tion to the medial paw site, while the plantar lateral area 
is exclusively innervated by branches of the sciatic nerve 
(14). In all animals of the ANG group (100%), return of 
sensation was seen after a time period of 9 weeks, when 
the response could already be detected upon light stimu-
lation representing hyperalgesia. In a similar manner, 
40% of the animals of the tf-neoSCs-FGF-218kDa group 
showed signs of sensory recovery. Based on experiments 
that included cutting of the saphenous nerve at the end 
of the observation period (not performed in the current 
study) the hypersensitivity in the lateral paw site can be 
attributed to the arrival of regenerating axons to this terri-
tory (15). Comparing ANG treatment to nerve reconstruc-
tion with tf-neoSCs-FGF-218kDa composite nerve conduits 
clearly indicates that regrowth of sensory fibers is sup-
ported to a greater extent by autologous nerve grafting.
Motor recovery was analyzed by means of electrophys-
iological examination at different time points after surgery. 
Similar to the findings related to sensory recovery, rein-
nervation of distal muscle targets and subsequent motor 
recovery was seen for all animals, which had received 
ANGs (100%) for nerve reconstruction and for 57% of 
the animals of the tf-neoSCs-FGF-218kDa group. Analysis 
of the lower hindlimb muscle weight ratios further indi-
cated progressing reduction of muscle atrophy attributable 
to muscle reinnervation. The fact that motor recovery after 
transplantation of tf-neoSCs-FGF-218kDa is ahead of sensory 
recovery is in accordance with our previous experiences 
(32) and to reports from in vitro studies describing more 
pronounced effects of FGF-218kDa on motor than on sensory 
neurite outgrowth (2). This distinguishable in vitro effect 
is also illustrated by our report of a strong neurite inducing 
effect of tf-neoSCs-FGF-218kDa in the PC12 cell assay and 
only a minimal effect in the DRG neurite outgrowth assay. 
Furthermore, the ANG is the standard therapy for bridging 
critical length sciatic nerve defects in the rat model and for 
this best and most complete sensory as well as motor recov-
ery, as detected also in the current study, can be expected 
(23). Transplantation of all other neoSC types did mainly 
result in failure of regeneration. We attribute this failure 
to mechanical impairments that possibly developed due to 
the secondary changes of NVR-Gel properties in vivo as 
discussed above.
Factors Contributing to Incomplete Motor Recovery 
After Tubular Nerve Repair
No definite solution for incomplete functional recov-
ery has been found so far. It is well established that top-
ographical peripheral motor and sensory projections of 
mixed nerves, for example, the sciatic nerve, are distorted 
during the regeneration process and that this hampers 
full functional recovery especially over long nerve gaps 
(71,72). Structuring the lumen of tubular nerve conduits, 
for example, with hydrogels like in the current study, is 
thought to minimize this distortion. Furthermore, spe-
cific neurotrophic support of motor neurons and their 
regrowing axons, like, for example, with GDNF or FGF-
218kDa, has been established to induce preferential motor 
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reinnervation and to reduce growth of regenerating motor 
axons along sensory tracts (50). Within the target tissue, 
however, another obstacle to valid functional recovery 
can occur, which has been described as polyinnervation 
of neuromuscular junctions (66). Interestingly, it has been 
shown that endogenous expression of FGF-218kDa plays a 
critical role in limiting polyinnervation, as in mice lack-
ing FGF-218kDa expression, polyinnervation was described 
to be higher and related to decreased functional recovery 
of the facial nerve after lesion and repair in comparison 
to wild-type mice (64). The impact of polyinnervation of 
neuromuscular endplates on the outcome of functional 
motor recovery in the sciatic nerve model in rats is not 
yet investigated in detail. From the rat facial nerve model, 
however, some interesting adjunct attempts emerged that 
could also be helpful in the context of limb recovery, like, 
for example, the stabilization of microtubule assembly 
within the regenerating nerve (24).
Differential Effects of Overexpressed FGF-218kDa and 
GDNF Within Composite Nerve Conduits
In the current study, the delivery of FGF-218kDa helped 
to overcome the shortcomings of the composite nerve 
conduits, while delivery of GDNF did not. One reason for 
this difference could be linked to the behavior of the neu-
rotrophic factor overexpressing cells within the conduits. 
For tf-neoSCs-FGF-218kDa, we detected a higher metabolic 
activity after 24 h within the chitosan conduits than for 
tf-neoSCs-GDNF. Although the difference in metabolic 
activity was not significant, this indicates that tf-neoSCs-
FGF-2 were more intensively interacting with the NVR-
Gel and thereby eventually loosening the gel structure or 
simply populating it in a more homogenous way. In the 
following, it may have been easier for regenerating axons 
or host Schwann cells to enter the composite chitosan con-
duits. Still, the missing effect of GDNF was unexpected, 
since, for example, Patel et al. (58) could show that GDNF 
and laminin-blended chitosan conduits enhanced func-
tional and sensory peripheral nerve functional recovery 
across 10-mm gaps in rats. Also Kokai and colleagues (45) 
reported functional recovery across a long gap (15 mm), 
when delivering GDNF to the lesion site via microspheres. 
However, the failure of tf-neoSCs-GDNF to support 
regeneration through composite nerve conduits in the cur-
rent study underscores another hypothesis, namely that 
this factor may be especially effective in case of delayed 
repair and fails to promote regeneration when administered 
immediately after nerve transection (10,11,37,74,75).
The specific support of functional recovery after 
immediate nerve reconstruction with transplantation of 
tf-neoSCs-FGF-218kDa into composite nerve conduits, 
however, could have been expected based on previous 
experiences. It has been demonstrated that FGF-218kDa 
promotes neurite outgrowth from spinal motoneurons in 
vitro (2) as well as axonal elongation and myelination in 
vivo (68). Additionally, we showed before that FGF-218kDa 
delivered by tf-neoSCs into silicone tubes predominately 
supports motor recovery across rat sciatic nerve defects 
(32,33). In conclusion, tf-neoSCs-FGF-218kDa incorpo-
rated into composite nerve conduits support peripheral 
nerve regeneration in general and motor recovery in par-
ticular. This may not only be attributed to specific action 
of the delivered protein on motor axons but also on its 
effect on the local host SCs in the bridged nerve ends. 
Transgenic mice overexpressing FGF-2 displayed an 
increased number of proliferating SCs as well as more 
axons 1 week after nerve crush (42). An increased SC 
migration due to locally increased levels of FGF-218kDa 
may have been the basis for increased axonal growth into 
the tf-neoSCs-FGF-218kDa composite nerve conduits and 
subsequent functional recovery in the current study.
CONCLUSION AND PERSPECTIVE
We demonstrate here that genetic engineering of SCs 
is a valuable tool for peripheral nerve tissue engineering. 
Especially FGF-218kDa delivery by these cells is able to 
increase functional recovery through composite nerve 
conduits. We further have to realize that 0.5% NVR-Gel 
is an optimal matrix to analyze peripheral nerve regenera-
tion in vitro but does in its current composition not guar-
antee for the same in vivo. Further attempts are needed 
to optimize composite chitosan nerve conduits in order 
to provide structural support as well as cell-based drug 
delivery systems for long nerve gap repair. As the main 
components of NVR-Gel (hyaluronic acid and laminin) 
are known to potentially support peripheral nerve regen-
eration, modifications of the gel would be an option to 
improve its performance. Handling of a more soluble 
NVR-Gel, however, demonstrated the risk of sudden 
leakage of the NVR-Gel and minimized standardization 
of the composite nerve conduits. Consequently, standard-
ized and controlled cell delivery would no longer be pos-
sible. Therefore, conversion of the NVR-Gel into a solid 
state, for example, by freeze drying, seems to be intrigu-
ing. Once this has been established also cell delivery pro-
tocols to these modified composite nerve conduits can be 
established and investigated in future in vivo attempts.
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